Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at consumerstockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. ConsumerStockMovers.com (CSM) also look into these stocks; Amazon.com (AMZN), Tesla (TSLA), The Home Depot (HD), Costco Wholesale (COST), Walmart (WMT), and McDonald’s..
Recent VRDN Stock Price: $18.14
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
Julian Harrison analyst at BTIG reiterates coverage on Viridian Therapeutics (VRDN) stock in the energy sector with a Buy rating and has set VRDN's stock price target at $46.
TipRanks.com reports that Viridian Therapeutics currently has 5 analysts offering 12-month price targets on VRDN and the consensus is a Strong Buy rating with an average stock price target of $38.80. The most recent VRDN stock price we have is $18.14 and we are not making any VRDN forecasts at this time.
In addition, TradingView issued a Buy rating for VRDN over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRDN. consumerstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VRDN, please click here >>
Bluebird Bio, BLUE
Recent BLUE Stock Price: $2.86
Summary: bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.'The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent '-thalassemia (TDT).
Yaron Werber analyst at TD Cowen reiterates coverage on Bluebird Bio (BLUE) stock in the energy sector with a Hold rating and has not provided BLUE's stock price target.
TipRanks.com reports that Bluebird Bio currently has 2 analysts offering 12-month price targets on BLUE and the consensus is a Moderate Buy rating with an average stock price target of $9.00. The most recent BLUE stock price we have is $2.86 and we are not making any BLUE forecasts at this time.
In addition, TradingView issued a Strong sell rating for BLUE over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BLUE. consumerstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BLUE, please click here >>
Biogen, BIIB
Recent BIIB Stock Price: $239.29
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Jay Olson analyst at Oppenheimer reiterates coverage on Biogen (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at $280.
TipRanks.com reports that Biogen currently has 5 analysts offering 12-month price targets on BIIB and the consensus is a Strong Buy rating with an average stock price target of $306.60. The most recent BIIB stock price we have is $239.29 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a Neutral rating for BIIB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. consumerstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
Avid Bioservices, CDMO
Recent CDMO Stock Price: $4.64
Summary: Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States.
Jacob Johnson analyst at Stephens reiterates coverage on Avid Bioservices (CDMO) stock in the energy sector with a Buy rating and has set CDMO's stock price target at $15.
TipRanks.com reports that Avid Bioservices currently has 4 analysts offering 12-month price targets on CDMO and the consensus is a Strong Buy rating with an average stock price target of $13.00. The most recent CDMO stock price we have is $4.64 and we are not making any CDMO forecasts at this time.
In addition, TradingView issued a Strong sell rating for CDMO over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CDMO. consumerstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CDMO, please click here >>
The editors at consumerstockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
ConsumerStockMovers.com (CSM) is a no cost internet site and email newsletter built for investors who are interested in consumer discretionary stocks, consumer cyclical stocks, and consumer staples stocks. (CSM) aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind (CSM) consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by (CSM) contain timely information regarding stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
